CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2006-04-28): BMS' Baraclude and Sanofi Pasteur MSD's RotaTeq set for EU approval

Regulatory

BMS' Baraclude and Sanofi Pasteur MSD's RotaTeq set for EU approval

Last Updated: 2006-04-28 13:50:29 -0400 (Reuters Health)

LONDON (Agence de Presse Medicale for Reuters Health) - The Committee for Medicinal Products for Human Use (CHMP) announced on Friday it is backing Bristol-Myers Squibb's Baraclude (entecavir) to treat chronic hepatitis B and Sanofi Pasteur MSD's RotaTeq (rotavarius vaccine) to prevent rotavirus gastroenteritis in infants.

In a statement, the CHMP said it has adopted a positive opinion on Baraclude and is recommending the European Medicines Agency (EMEA) grants marketing authorisation.

The New England Journal of Medicine reported last month that a review of head-to-head studies showed Baraclude for hepatitis B is clinincally superior to GlaxoSmithKline's Epivir (lamivudine) and equally well tolerated.

Publication of the results in the journal came about a year after Baraclude gained marketing approval in the U.S.

GlaxoSmithKline reported on Thursday in its first-quarter results for 2006 a 12% fall in Epivir sales compared with the same three-month period in 2005 to 60 million pounds (86.5 million euros).

The CHMP said it is also recommending Sanofi Pasteur MSD's rotavirus vaccine RotaTeq to prevent rotavirus gastroenteritis in infants from six weeks of age.

The Food and Drug Administration in the U.S. in February approved the vaccine from U.S. licence holder Merck & Co. Analysts have forecast peak sales of RotaTeq in the U.S. will top $500 million.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.